On the 2nd, the first day Caregen was designated as an investment warning issue on the KOSDAQ, the stock fell in early trading.
As of 9:44 a.m. that day, Caregen was trading at 112,500 won, down 13,000 won (10.36%) from the previous session.
Caregen was designated that day by the Korea Exchange (KRX) as an investment warning issue. If the stock rises more than 40% over two days after the designation and closes above the price on the day before the designation, trading may be suspended once. Unless the decision is deferred, whether to lift the measure will be decided on the 13th.
Caregen's share price has jumped recently on expectations for the development of an oral obesity drug. In Jan. 2–30 alone, the stock surged 75%.
On the 30th of last month, Caregen also said its in-house dietary supplement peptide product "Coglutide" was approved by the U.S. Food and Drug Administration (FDA) as a new dietary ingredient (NDI). The same day, Caregen climbed intraday to 137,400 won, a 1-year high.